TY - JOUR
T1 - Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer
T2 - Individual Patient Data Meta-Analysis of Overall Survival
AU - Lee, Chee Khoon
AU - Davies, Lucy
AU - Wu, Yi Long
AU - Mitsudomi, Tetsuya
AU - Inoue, Akira
AU - Rosell, Rafael
AU - Zhou, Caicun
AU - Nakagawa, Kazuhiko
AU - Thongprasert, Sumitra
AU - Fukuoka, Masahiro
AU - Lord, Sally
AU - Marschner, Ian
AU - Tu, Yu Kang
AU - Gralla, Richard J.
AU - Gebski, Val
AU - Mok, Tony
AU - Yang, James Chih Hsin
N1 - Publisher Copyright:
© The Author 2017.
PY - 2017/6
Y1 - 2017/6
N2 - Background: We performed an individual patient data meta-analysis to examine the impact of first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy on overall survival (OS) in advanced non-small cell lung cancer (NSCLC). Methods: Data from trials comparing EGFR-TKI against chemotherapy in exon 19 deletion (del19) or exon 21 L858R (L858R) EGFR mutations patients were used. We performed Cox regression to obtain hazard ratios (HRs) and 95% confidence intervals (CIs). Impact of postprogression therapies was examined in exploratory analyses. All statistical tests were two-sided. Results: Six eligible trials (gefitinib = 3, erlotinib = 3) included 1231 patients; 632 received EGFR-TKI and 599 received chemotherapy. At a median 35.0 months follow-up, there were 780 deaths and 1004 progressions. There was no difference in OS between EGFR-TKI and chemotherapy (HR=1.01, 95% CI=0.88 to 1.17, P=.84). There was also no difference in OS for Del19 (n=682, HR=0.96, 95% CI=0.79 to 1.16, P=.68) and L858R (n=540, HR=1.06, 95% CI=0.86 to 1.32, P=.59) subgroups (Pinteraction = .47), or according to smoking status, sex, performance status, age, ethnicity, or histology. However, EGFR-TKI statistically significantly prolonged progression-free survival (PFS) overall (HR=0.37, 95% CI=0.32 to 0.42, P<.001) and in all subgroups. Following progression, 73.8% from the chemotherapy arm received EGFR-TKI, and 65.9% from the EGFR-TKI arm received chemotherapy. Nine percent from the EGFR-TKI arm received no further treatment vs 0.6% from the chemotherapy arm. Following disease progression, patients randomly assigned to EGFR-TKI had shorter OS than those randomly assigned to chemotherapy (12.8 months, 95% CI=11.4 to 14.3, vs 19.8 months, 95% CI=17.6 to 21.7). Conclusions: Despite statistically significant PFS benefit, there is no relative OS advantage with frontline gefitinib or erlotinib vs chemotherapy in EGFR-mutated NSCLC. This finding is likely due to the high rate of crossover at progression.
AB - Background: We performed an individual patient data meta-analysis to examine the impact of first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy on overall survival (OS) in advanced non-small cell lung cancer (NSCLC). Methods: Data from trials comparing EGFR-TKI against chemotherapy in exon 19 deletion (del19) or exon 21 L858R (L858R) EGFR mutations patients were used. We performed Cox regression to obtain hazard ratios (HRs) and 95% confidence intervals (CIs). Impact of postprogression therapies was examined in exploratory analyses. All statistical tests were two-sided. Results: Six eligible trials (gefitinib = 3, erlotinib = 3) included 1231 patients; 632 received EGFR-TKI and 599 received chemotherapy. At a median 35.0 months follow-up, there were 780 deaths and 1004 progressions. There was no difference in OS between EGFR-TKI and chemotherapy (HR=1.01, 95% CI=0.88 to 1.17, P=.84). There was also no difference in OS for Del19 (n=682, HR=0.96, 95% CI=0.79 to 1.16, P=.68) and L858R (n=540, HR=1.06, 95% CI=0.86 to 1.32, P=.59) subgroups (Pinteraction = .47), or according to smoking status, sex, performance status, age, ethnicity, or histology. However, EGFR-TKI statistically significantly prolonged progression-free survival (PFS) overall (HR=0.37, 95% CI=0.32 to 0.42, P<.001) and in all subgroups. Following progression, 73.8% from the chemotherapy arm received EGFR-TKI, and 65.9% from the EGFR-TKI arm received chemotherapy. Nine percent from the EGFR-TKI arm received no further treatment vs 0.6% from the chemotherapy arm. Following disease progression, patients randomly assigned to EGFR-TKI had shorter OS than those randomly assigned to chemotherapy (12.8 months, 95% CI=11.4 to 14.3, vs 19.8 months, 95% CI=17.6 to 21.7). Conclusions: Despite statistically significant PFS benefit, there is no relative OS advantage with frontline gefitinib or erlotinib vs chemotherapy in EGFR-mutated NSCLC. This finding is likely due to the high rate of crossover at progression.
UR - http://www.scopus.com/inward/record.url?scp=85027265241&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85027265241&partnerID=8YFLogxK
U2 - 10.1093/jnci/djw279
DO - 10.1093/jnci/djw279
M3 - Article
C2 - 28376144
AN - SCOPUS:85027265241
SN - 0027-8874
VL - 109
JO - Journal of the National Cancer Institute
JF - Journal of the National Cancer Institute
IS - 6
M1 - djw279
ER -